Treatment of Botulism in Infants Under 1 Year of Age Acquired from Food or the Environment
Clinical Scenario
This protocol applies to infants aged under 1 year who develop botulism following exposure to toxin through food or the environment. When an infant presents as part of a cluster of botulism cases, a food or environmental source of toxin is the likely route of exposure, and the illness should be managed as botulism in an infant rather than the distinct syndrome of infant botulism.
Age-Specific Considerations
Infants under 1 year represent a distinct patient group in botulism management. Clinical decision-making and antitoxin dosing in this population are defined specifically for this age group, independent of body weight, and differ meaningfully from adult standards.
Treatment Approach & Goals
Clinical Goal
Management involves supportive care — including respiratory support when clinically indicated — alongside timely administration of botulinum antitoxin, with dosing calibrated specifically for the infant age group. The treatment aim is to halt the progression of flaccid paralysis; neurologic signs should not continue to worsen beyond one day after antitoxin is given. Complete sequencing, clinical criteria, and the full regimen are available in the structured protocol.
Full protocol details, including dosing, administration route, and clinical decision criteria, are accessible below.
References
- If an infant is affected as part of a group of botulism cases, the infant has likely been exposed to a toxin from food or the environment, and the illness is likely to be botulism in an infant rather than the syndrome of infant botulism.
- The FDA-approved BAT dose for infants (persons aged <1 year) is 10% of the adult dose, regardless of weight.
- Treatment involves supportive care, intubation and mechanical ventilation when necessary, and administration of equine-derived botulinum antitoxin.
- In such circumstances, the infant should receive BAT and be treated using these guidelines.
- When administered early in the course of illness (within 48 hours of symptom onset and ideally within 24 hours), botulinum antitoxin can stop the progression of paralysis and prevent respiratory compromise in certain patients.
View source ↗